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Objective: To determine the minimal clinically important difference (MCID) for the health-utility measures
EuroQol-5 dimensions (EQ-5D) and Quality of Well Being Self-Administered (QWB-SA) Scale in PTSD patients.
Research design and methods: Two hundred patients aged 18 to 65 years with PTSD enrolled in a doubly
randomized preference trial (DRPT) examining the treatment and treatment-preference effects between cognitive
behavioral therapy and pharmacotherapy with sertraline and completed the EQ-5D and QWB-SA at baseline and
10-week post-treatment. The anchor-based methods utilized a Clinical Global Impression-Improvement (CGI-I) and
Clinical Global Impression-Severity. We regressed the changes in EQ-5D and QWB-SA scores on changes in the
anchors using ordinary least squares regression. The slopes (beta coefficients) were the rates of change in the
anchors as functions of change in EQ-5D and QWB, which represent our estimates of MCID. In addition, we
performed receiver operating characteristic (ROC) curve analysis to examine the relationship between the changes
in EQ-5D and QWB-SA scores and treatment-response status. The MCIDs were estimated from the ROC curve where
they best discriminate between treatment responders and non-responders. The distribution-based methods used
small to moderate effect size in terms of 0.2 and 0.5 of standard deviation of the pre-treatment EQ-5D and QWB-SA
scores.
Results: The anchor-based methods estimated the MCID ranges of 0.05 to 0.08 for the EQ-5D and 0.03 to 0.05
for the QWB. The MCID ranges were higher with the distribution-based methods, ranging from 0.04 to 0.10 for
the EQ-5D and 0.02 to 0.05 for the QWB-SA.
Conclusions: The established MCID ranges of EQ-5D and QWB-SA can be a useful tool in assessing meaningful
changes in patient’s quality of life for researchers and clinicians, and assisting health-policy makers to make
informing decision in mental health treatment.
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Posttraumatic stress disorder (PTSD) is a chronic and de-
bilitating condition, with lifetime prevalence rates ranging
from 8%–14% of the US population [1]. Moreover, given
recent estimates of PTSD among Operation Iraqi Freedom
(OIF) and Operation Enduring Freedom (OEF) veterans,
there is an unprecedented need for empirically-supported
PTSD treatment for military personnel and veterans [2].
PTSD is associated with poor quality of life in multiple
health domains [3-5] and also has a huge financial burden
[5]. Greenberg and colleagues (1999) [6] reported that
through work impairment, hospitalization, and health visits,
PTSD was more costly than any other anxiety disorder.
Among the 1.64 million veterans returning from OEF and
OIF, it is estimated that approximately 300,000 individuals
currently suffer from PTSD or major depression, potentially
costing $4.0 to $6.2 billion in a two-year time frame [7].
These considerations highlight the substantial impact of
PTSD and the need for reliable and valid measures of
improved clinical outcomes.
Clinically, the PTSD Symptom Scale-Interview (PSS-I)
[8], PTSD Checklist (PCL) [9], and Clinician-Administered
PTSD Scale (CAPS) [10] have been the most commonly
used measures for assessing symptomatic improvement/
deterioration in clinical trials. In addition, patient-reported
outcome (PRO) instruments have been increasingly uti-
lized to supplement to the clinical measures and provide
additional information on other health-related quality of
life (HRQOL) domains (mobility, self-care, usual activities,
pain/discomfort, social, emotional, and physical functions)
as well as health utilities [5,11-14]. For example, to justify
the cost of a new intervention in PTSD, health-policy
makers would need to determine not only whether the new
intervention provides significantly clinical improvement but
also whether the new intervention is cost-effective as com-
pared to the current standard treatment. Incorporating
generic health-utility measures such as the EQ-5D, QWB-
SA, Health Utility Index Mark 3 (HUI3), or Short Form-6
dimensions (SF-6D) can allow comparisons of burden of
disease across health conditions as well as the quality-
adjusted live years (QALYs), a HRQOL measure used to
evaluate the cost-effectiveness for healthcare interventions.
Nevertheless, interpretation of a change in HRQOL score
from pre- to post-treatment can be confusing to clinicians
and other health professionals due to their unfamiliarity
with the PRO instruments. In contrast, repeated experience
and familiarity with clinical measures such as Body Mass
Index (BMI) or blood pressure allow health professionals to
make meaningful interpretation of the measures [15].
Thus, by placing the magnitude of change in HRQOL
score corresponding to a minimal clinically important
difference would be helpful and meaningful for health
professionals, patients, health-policy makers as well as
other stakeholders [15].In general, the minimal clinically important difference
(MCID) of a PRO instrument is defined as smallest change
in a PRO measure that is linked to a clinically relevant
difference or change. In other words, MCID is the smallest
difference that patients perceived as beneficial or harmful
and that would result in a change in treatment [16]. There
are two broad methods for estimating the MCID of a PRO
instrument: (1) anchor-based methods, which link changes
in HRQOL scores to external indicators either clinical or
patient-based such as laboratory or physiological measures,
and clinician or patient ratings; and (2) distribution-based
methods, which estimate MCIDs using small to medium
effect sizes based on the distribution of HRQOL scores in
a relevant sample [17]. Nevertheless, since no single
anchor is ideal and no single method is perfect, it is
recommended that multiple approaches from both
anchor- and distribution-based methods should be used
to estimate the MCID for a PRO instrument [17].
Empirical work on MCIDs for the EQ-5D or QWB-SA
has been done on several conditions [15,18-23]; however
it has not performed in mental health disorders, particu-
larly in PTSD. In the current study, we estimated and
compared the smallest changes in HRQOL utility scores
of EQ-5D and QWB-SA that can be regarded as clinic-
ally important in PTSD patients using multiple anchor-
and distribution-based approaches.
Patients and methods
Data for analysis were from the Optimizing PTSD
Treatment (OPT) trial (Clinicaltrials.gov; Identifier:
NCT00127673). The OPT trial is a hybrid efficacy-
effectiveness trial designed to better understand per-
sonalized PTSD treatment in two clinics at University
of Washington, Seattle, WA, and Case Western Reserve
University, Cleveland, OH. The OPT trial included patients
between the age of 18 and 65 years, who were currently
diagnosed with primary PTSD based on DSM-IV criteria,
with a minimum duration of 12 weeks since the traumatic
event and diagnosed using the PTSD Symptom Scale-
Interview Version (PSS-I) [8]. Patients were excluded from
the trial if they had one of the following: A current diagno-
sis of schizophrenia or delusional disorder; medically
unstable bipolar disorder, depression with psychotic fea-
tures, or depression severe enough to require immediate
psychiatric treatment (e.g. actively suicidal); a current diag-
nosis of alcohol or substance dependence in the previous
three months; an ongoing intimate relationship with per-
petrator (in assault cases); unwillingness to discontinue
current trauma-focused psychotherapy or anti-depressant
medication (depending on the assigned treatment arm) or
discontinuation was not medically advisable; either previous
nonresponse to prolonged exposure or sertraline; and
medical contraindication for the initiation of medication
(e.g. pregnancy or lactation). Patients were randomly
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tions, using a doubly randomized preference trial design
(DRPT). In the choice condition, patients chose treatment
between prolonged exposure therapy (PE) and pharmaco-
therapy with sertraline (SER). In the no-choice condition,
patients were randomly assigned to either PE or pharma-
cotherapy (Figure 1). Patients received 10 weeks of acute
treatment. Clinical and HRQOL measures were obtained
from all willing patients at pre- and post-treatment, and at
3-, 6-, and 12-month follow-up.
HRQOL health-utility instruments
The EQ-5D is a five-item self-administered questionnaire
and one of the most widely used generic preference-based
measures for estimating health utilities. The measure has
5 health domains (mobility, self-care, usual activities,
pain/discomfort, and anxiety/depression), each with three
response-levels: no problems, some problems, and severe
problems [24]. The scoring system of EQ-5D used in this
study was based on the U.S. population-based EQ-5D
[25] ranging from −0.11 (all five ED-5D health domains
reported extreme problems) to 1 or perfect health (no
problems at all five EQ-5D domains), in which zero means
dead and negative utility scores represent health states
worse than dead.
The QWB-SA is also a common generic preference-
based HRQOL measuring health utilities. Overall, the
QWB-SA includes five parts: (1) Part I asks about 19
chronic symptoms or problems (yes/no question format),
25 acute physical symptoms and 11 mental health symp-
toms over the last 3 days (in the format of whether the
symptom occurs “yesterday,” “2 days ago,” and/or “3 days
ago”); (2) Part II uses a similar format but asks about self-
care; (3) Part III asks about mobility; (4) Part IV ask about
physical functioning; and (5) Part V asks about social
activities. In all, the domain scores are combined into a sin-
gle index score ranging from 0.09 (lowest possible health
state) to 1 for perfect health, with zero means dead [26].Figure 1 The Optimizing PTSD Treatment (OPT) Trial.Anchors
The Clinical Global Impression (CGI) is a brief clinician-
rated instrument assessing: (1) severity of illness (CGI-S)
using a 7-point Likert scale: 1 or “normal, not mentally ill,”
2 or “borderline mentally ill,” 3 or “mildly mentally ill,” 4 or
“moderately mentally ill,” 5 or “markedly mentally ill,” 6 or
“severely mentally ill,” and 7 or “among the most extremely
mentally ill;” and (2) global improvement or change (CGI-I)
also using a 7-point Likert scale: 1 or “very much im-
proved,” 2 or “much improved,” 3 or “minimally improved,”
4 or “no change,” 5 or “slightly worse,” 6 or “much worse,”
and 7 or “very much worse [27].
In addition to CGI-S and CGI-I, we also selected the
PTSD Symptom Scale-Interview (PSS-I) [8] as our third
anchor. Classification of treatment responder or non-
responder at 10-week post-treatment was assessed using
the PSS-I and CGI-I. The 17-item PSS-I uses DSM-IV
symptom criteria; and each symptom is rated on a 0 (not
at all) to 3 (5 or more times per week/very much) scale of
frequency and/or severity [7]. The absolute cutoff scores of
23 or less on the PSS-I and 3 or lower on the CGI-I define
the clinically meaningful improvement [28-30].
Statistical analysis
To be included in this analysis, a patient had to baseline or
pre-treatment and a follow-up assessment of EQ-5D,
QWB-SA, CGI-S, CGI-I, and PSS-I. For patients who had
multiple follow-up visits, the current analysis included the
first follow-up assessment on which all measures com-
pleted. All analyses in the study were conducted using Stata
release 12.0 (Stata Corp LP, College Station, TX, USA).
Anchor-based approach
Correlation coefficients between changes in EQ-5D scores
and changes in anchor measures were determined to con-
firm the usefulness of the anchors. A correlation coefficient
of 0.30 or more is needed in order to be considered a good
anchor [17].
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with “very much worse,” “much improved” with “much
worse,” and “minimally improved” with “slightly worse;”
and those on the worsening side of the scale, the sign of the
change in HRQOL health-utility scores is reversed, i.e.
negative sign to positive and vice versa. We regressed the
changes of the EQ-5D and QWB-SA scores on the
transformed CGI-I using ordinary least squares method.
The slopes (beta coefficients of the regression lines) were
the rates of change in the anchor CGI-I as functions of
change in EQ-5D and QWB-SA scores, which represented
the estimates of the MCID. This method helped to prevent
few worsening responses that may adversely affect the slope
of the regression line; thus the estimated MCIDs were more
stable and applicable to the entire scores of the EQ-5D and
QWB-SA as opposed to separate the scores into worsening
and improvement [31]. For the CGI-S anchor, to estimate
the MCIDs, we simply regressed the changes of the EQ-5D
and QWB-SA scores on the change of CGI-S between
pre-treatment and follow-up visit.
In our second anchor-based approach, we analyzed the
relationship between the changes in EQ-5D and QWB-SA
scores and the treatment response status using receiver
operating curve (ROC) analysis to estimate the MCIDs.
The ROC curves were constructed by plotting the sensi-
tivity (true-positive rate) against the one minus specificity
(false-positive rate) at different cut-off points in the con-
tinuous HRQOL score changes that distinguished treat-
ment responder and non-responder. The area under the
ROC cure (AUC) can be interpreted as the probability of
correctly discriminating between the treatment responder
and non-responder [32-35]. The AUC ranges from 0.5
(corresponds to no discriminatory ability, i.e. randomTable 1 Baseline demographic and clinical characteristics
NO-CHOICE (RANDOMIZATION)
PE SER
Number of Patients (%) 55 48




Education (College Educated) (%) 38.2% 23.0%
PTSD Severity (PSS-I), mean (SD) 29.7 (7.1) 29.6 (6.3)
Re-experiencing, mean (SD) 7.8 (2.7) 7.5 (3.0)
Avoidance, mean (SD) 12.3 (3.8) 11.9 (3.4)
Hyperarousal, mean (SD) 9.6 (3.3) 10.2 (2.5)
CGI-S, mean (SD) 4.6 (1.0) 4.5 (0.9)
EQ-5D, mean (SD) 0.67 (0.18) 0.60 (0.21)
QWB-SA, mean (SD) 0.58 (0.11) 0.57 (0.10)
SER, Pharmacotherapy with sertraline; PE, Prolonged Exposure Therapy; PTSD, Post-
Global Impression-Severity; EQ-5D, EuroQol Group-5 Dimensions; QWB-SA, Quality oresponding as with a coin flip to determine treatment-
response status) to 1.0 (corresponds to perfect discrimin-
atory ability, i.e. perfect prediction). Using ROC curve
analysis, the MCIDs were determined based on the
optimal cut-off points for the changes in HRQOL
scores which maximized the sensitivity and specificity,
i.e. point that best discriminated between patients who
were treatment responders and those who did not respond
to treatment [34,35].
Distribution-based approach
For distribution-based approach, the MCIDs can be
estimated as one half the standard deviations of the
pre-treatment EQ-5D and QWB-SA scores. The one
half the standard deviation at baseline of a HRQOL
measure (or moderate effect size) has been linked to
establish the MCID and used widely in literature [36].
Alternatively, a small effect size in terms of 0.2 the standard
deviations at pre-treatment EQ-5D and QWB-SA scores
were also utilized [37].
Results
Figure 1 provides the consort diagram for the OPT trial’s
doubly randomized preference design. Two hundred con-
firmed PTSD patients were first randomly assigned to the
choice (n = 97) and no-choice (n = 103) arms. In the
choice arm, 67 patients chose prolonged exposure therapy
while 36 patients chose pharmacotherapy with sertraline. In
the no-choice arm, patients were randomized again to PE
(n = 55) and SER (n = 48). Similar demographic and clinical
characteristics were observed across the four arms of the
trial (Table 1). In the overall sample, patients were between
moderately and markedly mentally ill (mean CGS-S = 4.6),CHOICE TOTAL
Subtotal PE SER Subtotal
103 61 36 97 200
37.5 (11.4) 37.1 (11.3) 38.3 (11.4) 37.5 (11.3) 37.5 (11.3)
78.6% 75.4% 69.4% 73.2% 76.0%
21.4% 24.6% 30.6% 26.8% 24.0%
31.1% 42.6% 22.2% 35.1% 33.0%
29.7 (6.7) 29.1 (6.8) 30.0 (6.7) 29.5 (6.7) 29.6 (6.7)
7.7 (2.9) 7.3 (2.7) 7.5 (2.8) 7.4 (2.7) 7.5 (2.8)
12.1 (3.6) 12.2 (3.1) 12.4 (3.1) 12.3 (3.1) 12.2 (3.3)
9.9 (2.9) 9.6 (2.9) 10.1 (3.1) 9.8 (3.0) 9.8 (3.0)
4.6 (1.0) 4.6 (1.1) 4.4 (0.9) 4.5 (1.0) 4.6 (1.0)
0.61 (0.20) 0.65 (0.17) 0.56 (0.19) 0.62 (0.18) 0.63 (0.19)
0.57 (0.11) 0.56 (0.10) 0.59 (0.11) 0.57 (0.10) 0.57 (0.11)
traumatic Stress Disorder; PSS-I, PTSD Symptom Scale-Interview; CGI-S, Clinical
f Well-Being-Self Administration.
Table 3 Changes in HRQOL health-utility scores and
clinical anchors between pre-treatment and follow-up
Measures N Mean (SD) Effect size
CGI-S 155 −2.6 (1.5) 2.06
CGI-I* 155 1.7 (1.1) N/A
PSS-I 155 17.9 (10.8) 2.03
Treatment Response† 155 130 (83.9%) N/A
EQ-5D 155 0.15 (0.22) 0.77
QWB-SA 155 0.09 (0.15) 0.64
HRQOL, Health-Related Quality of Life; SD, Standard Deviation; CGI-I, Clinical
Global Impression-Improvement; CGI-S, Clinical Global Impression-Severity;
PTSD, Post-traumatic Stress Disorder; PSS-I, PTSD Symptom Scale-Interview;
EQ-5D, EuroQol Group-5 Dimensions; QWB-SA, Quality of
Well-Being-Self Administration.
* Note that CGI-I was only given at post-treatment and thereafter.
† Treatment response was measured as number (n) and percent (%) of
patients who responded to treatment.
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not have 4-year college degree. Additionally, a wide range
of EQ-5D (0.17 to 1.0) and QWB-SA scores (0.22 to 0.86)
were observed. The overall mean of EQ-5D score was
larger than the mean QWB-SA score (0.63 ± 0.19 vs.
0.57 ± 0.11) (Table 1).
Table 2 shows the correlation coefficients between the
HRQOL health-utility measures (EQ-5D and QWB-SA)
and the clinical anchors (CGI-I, CGI-S, PSS-I, and treat-
ment response status). Overall, all the clinical anchors
were strongly correlated with the HRQOL health-utility
measures (Spearman’s Rho ranged from 0.35 to 0.44 with
significant alpha level < 0.001); thus were considered
appropriate anchors.
One hundred and fifty patients had all assessment of
EQ-5D, QWB-SA, CGI-S, CGI-I, and PSS-I at baseline
and at least one follow-up visit. Table 3 gives the mean
changes of the HRQOL health-utility scores and clinical
anchors between pre-treatment and follow-up visit. All
the changes in scores had medium or large effect sizes.
Of these 155 patients, 130 patients (83.9%) responded to
one of the therapies.
Table 4 summarizes the MCID estimates for the EQ-5D
and QWB-SA using multiple approaches from both
anchor- and distribution-based methods. The EQ-5D
MCID ranges from 0.05 to 0.08 using the anchor-based
approach and from 0.04 to 0.10 using distribution-based
approach. For the QWB-SA, using the anchor- and
distribution-based approaches resulted in the ranges of
MCID values from 0.02 to 0.05.
Figures 2 and 3 demonstrate the regression lines of the
changes of the EQ-5D and QWB-SA scores on the
transformed CGI-I and CGI-S. The beta coefficients of
the regression lines (the slopes) indicate the estimates of
the MCIDs (0.05 to 0.08 for the EQ-5D and 0.03 to 0.05
for the QWB-SA). Figure 4 shows the ROC curves with the
optimal cut-off points represented the MCIDs for the
EQ-5D and QWB-SA, respectively. For the EQ-5D
(AUC= 0.809; 95% CI: 0.721–0.897), at the optimal cut-off
point of 0.05 it maximized the sensitivity (0.71) andTable 2 Correlation coefficients between the HRQOL
health-utility measures (EQ-5D and QWB-SA) and the





CGI-I CGI-S PSS-I Treatment response
status
EQ-5D −0.35* 0.37* 0.44* 0.38*
QWB-SA −0.41* 0.39* 0.43* 0.38*
HRQOL, Health-Related Quality of Life; CGI-I, Clinical Global Impression-
Improvement; CGI-S, Clinical Global Impression-Severity; PTSD, Post-traumatic
Stress Disorder; PSS-I, PTSD Symptom Scale-Interview; EQ-5D, EuroQol Group-5
Dimensions; QWB-SA, Quality of Well-Being-Self Administration.
* Statistical Significance at α < 0.001.specificity (0.81). For the QWB-SA (AUC= 0.808; 95%
CI: 0.696–0.920), the optimal cut-off point of 0.03 resulted
in maximized sensitivity (0.73) and specificity (0.86).Discussion
Understanding changes in scores and how to interpret the
changes are critical in the field of HRQOL measurement.
Because there is no single gold-standard method for
estimating MCID, multiple methods from both anchor-
and distribution-based approaches and triangulation of all
the methods to establish a possible range of MCID are
recommended [17]. Using data from a doubly randomized
preference trial in post-traumatic stress disorder patients
(the OPT trial), our analysis suggests that the plausible
range of MCID values for the HRQOL health-utility
EQ-5D and QWB-SA in the population of PTSD patients
were between 0.04 and 0.10, and 0.02 to 0.05, respectively.
Empirical works on MCIDs for the EQ-5D or QWB-SA
has been done on several disease states and were ranged
from −0.01 to 0.14 [15,18-21]. However, those MCID
estimates for the EQ-5D were based on the U.K. scoring
algorithm or EQ-5D VAS instead of the U.S. scoring
method used in the current study. Two studies using the U.
S. population-based scoring model reported similar range
of MCID values between 0.07 and 0.09 for the EQ-5D
utility [18,20]. For the QWB-SA, our range of MCID values
was consistent with previous studies [22,23].
The clinical anchors (CGI-I, CGI-S, and PSS-I for classi-
fying treatment response status) used in our analysis were
most appropriate as they were highly clinically relevant and
strongly correlated with the HRQOL health-utility EQ-5D
and QWB-SA. In addition, the anchor-based approach
utilized well-established methods (OLS regression and
ROC curve analysis) to estimate the MCIDs and produced
rather similar results even if with different anchors used.
The AUCs resulted from ROC analysis were rather large
Table 4 Estimated Minimal Clinically Important Differences (MCIDs) and their 95% Confidence Intervals (CIs) for EQ-5D
and QWB-SA using both anchor- and distribution-based approaches
ANCHOR-BASED APPROACH DISTRIBUTION-BASED APPROACH
HRQOL health-utility CGI-I* CGI-S* Treatment response status† 0.2 SD 0.5 SD
EQ-5D 0.08 (0.04–0.11) 0.05 (0.03–0.07) 0.05 0.04 0.10
QWB-SA 0.05 (0.03–0.08) 0.03 (0.02–0.05) 0.03 0.02 0.05
HRQOL, Health-Related Quality of Life; CGI-I, Clinical Global Impression-Improvement; CGI-S, Clinical Global Impression-Severity; SD, Standard Deviation at baseline
or pre-treatment; EQ-5D, EuroQol Group-5 Dimensions; QWB-SA, Quality of Well-Being-Self Administration.
* Anchor-based approach using ordinary least squares regression method (also refer to Figures 2 and 3).
† Anchor-based approach using ROC curve analysis (also refer to Figure 4).
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health-utility measures had great ability to discriminate
correctly treatment responders from non-responders.
Although multiple methods are necessary to estimate a
range of MCID values, Revicki and colleagues (2008) [17]
further recommended that results from the anchor-based
approach have the most weight due to their clinical advan-
tages over the distribution-based approach. That is, it is
more likely that the ranges of MCID values in the popula-
tion of PTSD patients would be between 0.05 to 0.08 and
0.03 to 0.05 for the EQ-5D and QWB-SA, respectively.
Both EQ-5D and QWB-SA are assumed to measure
the same underlying construct of overall HRQOL in
terms of health utility. The primary use of HRQOL
health-utility measures is to calculate the quality-
adjusted life year (QALY), a function of both quantity
and quality of life, which is used in health economic
evaluations and decision models to help health policy
makers to allocate resources effectively. Therefore, it is im-
portant to establish their MCIDs and then compare them
between the EQ-5D and QWB-SA. Our results showed
that the plausible range of MCID values for the EQ-5DFigure 2 EQ-5D and QWB-SA versus CGI-I-Scatter Plot and Regressionwas almost twice that of the range for the QWB-SA. It was
more likely because the two HRQOL health-utility instru-
ments: (1) measure different health state descriptive
systems thus different number of possible health states
(243 possible health states for the EQ-5D versus 945 for
the QWB-SA), (2) assess preferences for the multiple
health states using different methods, i.e. time-trade off
method used for the EQ-5D and rating-scale for the
QWB-SA, and (3) use different scoring functions.
There were, however, some limitations in the current
analysis. First, we did not apply multiple imputation
methods for the missing data. Instead, we assumed that
any missing assessments of the clinical anchors and
HRQOL health-utility measures were missing com-
pletely at random (MCAR), meaning that our results
would be similar whether or not there were missing
data. Secondly, as there were very few worsening cases,
the anchor-based methods focused mainly on the
responses of those who were clinically improved rather
than those worsened. Future work to assess the MCIDs
for those who are clinically worsened is in need. Never-
theless, more than often the MCID is used in theLine.
Figure 3 EQ-5D and QWB-SA versus CGI-S-Scatter Plot and Regression Line.
Le et al. Health and Quality of Life Outcomes 2013, 11:59 Page 7 of 9
http://www.hqlo.com/content/11/1/59context of a treatment effect, thus the MCID results
in our study can still be applied to detect minimal
clinically improvement in score changes. Finally, in
our study, CGI-I questions were given to patients at
10-week post-treatment. The main limitation of
using anchor-based approach that relies on global
ratings is that these retrospective ratings are poten-
tially susceptible to recall bias. As discussed above,
it is important to estimate a range of MCID values
from several different methods rather than a point
estimate.Figure 4 ROC Curves of EQ-5D and QWB-SA with Optimal Cut-off PoiOur analysis to determine the plausible ranges of MCID
values for the EQ-5D and QWB-SA followed the recom-
mendations by Revicki and colleagues (2008) [17]: longitu-
dinal data were obtained from the clinical trial, multiple
anchors were used and they were highly clinically relevant
and strongly correlated with the HRQOL instruments,
methodologically sound methods utilizing OLS regression
and ROC curve analysis were applied in the anchor-based
approach, and triangulation of multiple methods using both
anchor- and distribution-based approaches to produce
plausible ranges of MCID values.nts.
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To our knowledge, this analysis is the first attempt to
use multiple anchors-based approach as well as
distribution-based approach to determine and compare
the MCID ranges for the EQ-5D and QWB-SA in the
population of PTSD patients. The information can be help-
ful in interpreting the EQ-5D and QWB-SA scores as well
as in planning new trials when estimating power and sam-
ple sizes [15]. Furthermore, the established MCID ranges of
EQ-5D and QWB-SA can be a useful tool in assessing
meaningful changes in patient’s quality of life for re-
searchers and clinicians, and assisting health-policy makers
to make informing decision in mental health treatment.
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